



FINAL REPORT

Bill No.	: MGMWPR240092225	Bill Date	: 14-10-2024 11:02
Patient Name	: MR. KIRAN BHAGWAN TAWARE	UHID	: MGM240017131
Age / Gender	: 56 Yrs 2 Mth / MALE	Patient Type	: IPD If PHC :
Ref. Consultant	: DR.PRASHANT ATHALE	Ward	: SICU
Sample ID	: MGM24153534	Current Bed	: SICU-011
IP Number	: MGMIP2406720	Reporting Date & Time	: 17-10-2024 15:28
		Receiving Date & Time	: 14/10/2024 11:17

Microbiology Report

BLOOD - C/S - 2 - BAC ALERT

Specimen : Blood
Site : Arterial site

Remarks : Central & Peripheral site shows No growth after 3 days of incubaton.

Organism : Acinetobacter baumannii

ANTIBIOTICS	INTERPRETATION	MIC
Amikacin	RESISTANT	>=64
Amoxicillin/Clavulanic acid	RESISTANT	Disc diffusion
Cefotaxime	RESISTANT	Disc diffusion
Ceftriaxone	RESISTANT	Disc diffusion
Cefuroxime	RESISTANT	Disc diffusion
Cefoperazone	RESISTANT	Disc diffusion
Ceftazidime	RESISTANT	>=64
Gentamicin	SENSITIVE	<=1
Netilmicin	SENSITIVE	Disc diffusion
Ciprofloxacin	RESISTANT	>=4
Levofloxacin	RESISTANT	Disc diffusion
Trimethoprim/Sulphamethoxazole	RESISTANT	160
Piperacillin/Tazobactam	RESISTANT	>=128
Colistin	SENSITIVE	<=0.5
Cefepime	RESISTANT	>=32
Imipenem	RESISTANT	>=16
Meropenem	RESISTANT	>=16
Cefaperazone/Sulbactam	RESISTANT	>=64
Ticarcillin/Clavulanic acid	RESISTANT	Disc diffusion
Polymyxin B	SENSITIVE	1
Tigecycline	SENSITIVE	<=0.5
Minocycline	SENSITIVE	<=0.5

Method :- Culture- Aerobic by Automated BACT/ ALERT 3D. Identification done by Biochemical reactions / Automated Vitek-2 .
Antimicrobial sensitivity by automated Vitek -2 / conventional methods/estrips.

Note :-

1. Result of culture and antimicrobial susceptibility test need to be correlated clinically.
2. Previous history of antibiotic usage may influence the growth of microorganisms in vitro.
3. Antibiotic susceptibility done as per revised CLSI Guidelines.

Clinical Reference :

1. CLSI: Performance standards for Antimicrobial Susceptibility Testing.

*****End of the Report*****